214 related articles for article (PubMed ID: 28864947)
21. Analytical approaches to minimizing immeasurable time bias in cohort studies.
Oh IS; Baek YH; Jeong HE; Filion KB; Shin JY
Int J Epidemiol; 2021 Jul; 50(3):987-999. PubMed ID: 33367629
[TBL] [Abstract][Full Text] [Related]
22. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis.
Yang A; Zylberberg HM; Rustgi SD; Amin SP; Bar-Mashiah A; Boffetta P; Lucas AL
Sci Rep; 2021 Jan; 11(1):1038. PubMed ID: 33441781
[TBL] [Abstract][Full Text] [Related]
23. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study.
Kirkegård J; Cronin-Fenton D; Lund A; Mortensen FV
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5726. PubMed ID: 37946571
[TBL] [Abstract][Full Text] [Related]
24. Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer.
Cui Y; Wen W; Zheng T; Li H; Gao YT; Cai H; You M; Gao J; Yang G; Zheng W; Xiang YB; Shu XO
Am J Epidemiol; 2019 Aug; 188(8):1512-1528. PubMed ID: 31062847
[TBL] [Abstract][Full Text] [Related]
25. Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma.
Udumyan R; Montgomery S; Fang F; Almroth H; Valdimarsdottir U; Ekbom A; Smedby KE; Fall K
Cancer Res; 2017 Jul; 77(13):3700-3707. PubMed ID: 28473530
[TBL] [Abstract][Full Text] [Related]
26. Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancers.
Charvat H; Bossard N; Daubisse L; Binder F; Belot A; Remontet L
Cancer Epidemiol; 2013 Dec; 37(6):857-63. PubMed ID: 24063904
[TBL] [Abstract][Full Text] [Related]
27. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
[TBL] [Abstract][Full Text] [Related]
28. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study.
Anker MS; Ebner N; Hildebrandt B; Springer J; Sinn M; Riess H; Anker SD; Landmesser U; Haverkamp W; von Haehling S
Eur J Heart Fail; 2016 Dec; 18(12):1524-1534. PubMed ID: 27910284
[TBL] [Abstract][Full Text] [Related]
29. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
Kowall B; Stang A; Rathmann W; Kostev K
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
[TBL] [Abstract][Full Text] [Related]
30. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Hicks BM; Murray LJ; Powe DG; Hughes CM; Cardwell CR
Ann Oncol; 2013 Dec; 24(12):3100-6. PubMed ID: 24050955
[TBL] [Abstract][Full Text] [Related]
31. Immortal Time Bias in National Cancer Database Studies.
Newman NB; Brett CL; Kluwe CA; Patel CG; Attia A; Osmundson EC; Kachnic LA
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):5-12. PubMed ID: 31404580
[TBL] [Abstract][Full Text] [Related]
32. Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study.
Shah SM; Carey IM; Owen CG; Harris T; Dewilde S; Cook DG
Br J Clin Pharmacol; 2011 Jul; 72(1):157-61. PubMed ID: 21453301
[TBL] [Abstract][Full Text] [Related]
33. Metformin and pancreatic cancer survival: Real effect or immortal time bias?
Wei M; Liu Y; Bi Y; Zhang ZJ
Int J Cancer; 2019 Oct; 145(7):1822-1828. PubMed ID: 30848544
[TBL] [Abstract][Full Text] [Related]
34. Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: evidence from methods that avoid immortal time bias.
Zhang HS; Yang Y; Lee S; Park S; Nam CM; Jee SH
Int J Colorectal Dis; 2022 Aug; 37(8):1827-1834. PubMed ID: 35831458
[TBL] [Abstract][Full Text] [Related]
35. Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer.
Udumyan R; Montgomery S; Fang F; Valdimarsdottir U; Hardardottir H; Ekbom A; Smedby KE; Fall K
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):119-126. PubMed ID: 31641010
[TBL] [Abstract][Full Text] [Related]
36. Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Cardwell CR; Coleman HG; Murray LJ; O'Sullivan JM; Powe DG
Cancer Epidemiol; 2014 Jun; 38(3):279-85. PubMed ID: 24786858
[TBL] [Abstract][Full Text] [Related]
37. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
Zeng C; Wen W; Morgans AK; Pao W; Shu XO; Zheng W
JAMA Oncol; 2015 Apr; 1(1):88-96. PubMed ID: 26182310
[TBL] [Abstract][Full Text] [Related]
38. Adjusting relative survival estimates for cancer mortality in the general population.
Ellison LF
Health Rep; 2014 Nov; 25(11):3-9. PubMed ID: 25408490
[TBL] [Abstract][Full Text] [Related]
39. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study.
Mi X; Hammill BG; Curtis LH; Lai EC; Setoguchi S
Stat Med; 2016 Nov; 35(26):4824-4836. PubMed ID: 27350312
[TBL] [Abstract][Full Text] [Related]
40. Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Wilts IT; Hutten BA; Meijers JCM; Spek CA; Büller HR; Kamphuisen PW
Thromb Res; 2017 Jun; 154():1-6. PubMed ID: 28376316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
